Major Depressive Disorder (MDD)
Pipeline by Development Stage
Drug Modality Breakdown
On Market (6)
Approved therapies currently available
Competitive Landscape
26 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
Showing 15 of 31 trials with date data
Clinical Trials (31)
Total enrollment: 13,583 patients across 31 trials
Open-label Brexpiprazole fMRI Trial in Adults With Major Depressive Disorder and Anxiety
Cardiovascular Effects of Agomelatine and Escitalopram in Patients With Major Depressive Disorder (MDD)
A Duloxetine Dosing Strategy Study in Korean Patients With Major Depressive Disorder
Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder
A Study to Evaluate the Efficacy and Safety of Ansofaxine Hydrochloride Extended-release Tablets in the Treatment of Major Depressive Disorder (MDD)
Brexpiprazole as Adjunctive Therapy With Major Depressive Disorder and an Inadequate Response to Previous Adjunctive Therapy
To Assess the Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)
Efficacy, Safety and Tolerability of Agomelatine in the Treatment of Major Depressive Disorder
Effects of Antidepressants on Sexual Functioning
Effects Of Antidepressants On Sexual Functioning In Adults
Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder
A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression
Dextromethorphan-Bupropion on Striatal Activity in Adults With Major Depressive Disorder
ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response
An Open-Label Extension Study to Evaluate the Safety and Tolerability of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 OLE Study)
A Phase 2 Study to Evaluate Efficacy and Safety of KH607 Tablets in Adult Participents With Major Depressive Disorder
A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)
Study Of Bupropion SR (323U66) In Patients With Major Depressive Disorder In Japan
An 8 Week Depression Study In Adults Diagnosed With Major Depressive Disorder
Prediction of REsponse to Depression Interventions (Accelerated rTMS) Using Clinical and TD-fNIRS Measurements
Home-Based tDCS Treatment Of Major Depressive Disorder
Efficacy of Dextromethorphan-Bupropion Versus SSRIs in the Treatment of Major Depressive Disorder
Cognitive Rehabilitation for Veterans With MDD-related Cognitive Functioning Deficits
NQ TMS for MDD Therapy Using 1 Day x 3 Sessions Protocol for Adult Patient
Non-invasive Brain Stimulation in Subjects with Major Depressive Disorder
Efficacy of H7-Coil DTMS Compared to H1-Coil DTMS in Subjects With Major Depression Disorder (MDD)
European Drug Utilization Study
Retrospective TMS Therapy for Adults With MDD
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.